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Objectives: To estimate cost-effectiveness of adding human papillomavirus (HPV) 
vaccine to Brazil National Immunization Program, compared with the current strat-
egy for control of cervical cancer, the screening program based on conventional 
Papanicolaou citology. MethOds: We used a static decision tree analysis model, 
CERVIVAC, software developed by PAHO ProVac Initiative. The model compared two 
strategies: 1) a cohort of girls aged 10 years to represent the epidemiological situation, 
current screening, and care of precursor lesions and cancer (without vaccination) with 
2) a cohort of girls aged 10 years who were applied 3 doses of HPV vaccine, maintain-
ing the conditions of screening and care of precursor lesions and cancer, as they are 
currently. National parameters for the epidemiology of cervical cancer, screening 
expenditures and National Cervical Cancer Control Program were estimated in depth. 
The estimates were based on the health information systems of the Public Health 
System, SUS (SIH, SIA, APAC, SIAB, SIGTAP and SISCOLO), national survey (PNAD 2008) 
and relevant national literature. Results: The vaccine introduction would reduce the 
burden of disease. The model estimated 261 deaths avoided and 7595 DALYs averted, 
in each successive cohort to be vaccinated. The ICER per DALY averted R$ 18,121 would 
be considered cost-effective, according to the parameters adopted by WHO. In univari-
ate sensitivity analysis, only a lower discount rate and a high incidence and mortality 
would make the introduction of the vaccine very cost-effective. cOnclusiOns: The 
vaccine introduction should bring benefits for the control of cervical cancer, but it will 
require large investments by the NIP. It should be guaranteed the right conditions for 
the immunization program sustainability and equity in a population perspective as 
well as to improve the screening program.
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ObjectivOs: Evaluar el perfil costo efectividad de everolimus en combinación 
con exemestano en pacientes con cáncer de mama avanzado, RE+, HER2–, que 
fallaron a los IANES. MetOdOlOgíAs: Se desarrolló un modelo de Markov con 
ciclos mensuales y un horizonte temporal de diez años. El modelo compara a) 
exemestano+everolimus seguido por tres líneas de quimioterapia y mejor tera-
pia de soporte (MTS) con b) tres líneas de quimioterapia más MTS. Se incluyó la 
probabilidad de muerte desde cualquier tratamiento. La secuencia de quimiotera-
pia se definió a través de un panel de expertos. Las probabilidades de transición 
para everolimus+exemestano se obtuvieron del estudio BOLERO-2. Se realizó una 
revisión de la literatura para las probabilidades de transición de las quimioterapias. 
Se incluyeron los costos de los medicamentos y de su administración, los costos 
asociados con eventos adversos, monitoreo y de la MTS. Los resultados se presentan 
en $MXN de 2012 desde una perspectiva del Sistema Público de Salud mexicano. 
Se aplicó una tasa de descuento del 5% para costos y efectividades. Se realizaron 
análisis de sensibilidad probabilístico (ASP) con mil repeticiones y diferentes análisis 
de sensibilidad univariados, incluyendo un análisis con horizonte temporal de por 
vida. ResultAdOs: El modelo mostró que everolimus+exemestano resulta en 1.32 
años de vida ganados con un costo incremental de $314,327 dando como resultado 
una razón de costo efectividad incremental (RCEI) de $237,902. El ASP mostró que 
la RCEI está dentro del rango recomendado por la OMS (1 a 3 PIBs per capita) en 
la mayoría de los casos. La RCEI con un horizonte temporal de por vida fue de 
$209,292. cOnclusiOnes: El presente análisis mostró que utilizar everolimus más 
exemestano en pacientes con cáncer de mama avanzado, RE+, HER2–, que fallaron a 
los IANES es una opción costo efectiva de acuerdo a las recomendaciones de la OMS.
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ObjectivOs: Evaluar la costo-efectividad de Erlotinib como tratamiento en primera 
línea (1L) de pacientes con cáncer pulmonar de células no pequeñas, CPCNP estadio 
IIIB/IV, con mutación del gen EGFR+, en comparación con la quimioterapia estándar 
(carboplatino/ Paclitaxel) y con Getinib, desde la perspectiva del Sistema de Salud 
Colombiano. MetOdOlOgíAs: Se empleó un Modelo de Markov que simula el curso 
del CPCNP, con ciclos mensuales. Los estados de salud considerandos en el modelo 
son: Libre de progresión de enfermedad (LPE), Libre de progresión de enfermedad 
con respuesta (LPER), Progresión de enfermedad (PE); y Muerte. Se consideran cos-
tos directos y eventos adversos en pesos colombianos, años de vida ganados libres 
de enfermedad (AVGLE), para Erlotinib y Gefitinib comparados con quimioterapia 
estándar. Las probabilidades de transición se tomaron de la literatura, los costos se 
obtuvieron a partir de consenso de expertos según la práctica habitual, los costos de 
Objectives: To determine 1-year direct medical costs of treating patients with 
Chronic Lymphoid Leukemia (CLL) from the Brazilian Private Healthcare System 
perspective. MethOds: The Orizon database, an administrative database contain-
ing inpatient and outpatient claims to a pool of 102 HMOs representing 34% of the 
total Private Health System, was reviewed from Jan/2009 to Dec/2012. Eligibility 
criteria were patients starting CLL (ICD-10 code C911) treatment from Apr/2009 to 
Dec/2011. Outcome was direct medical costs (DMC) per patient-year, calculated 
as the sum of the medical claims for each patient included in the analysis, for a 
maximum period of 12-months or death or loss of follow-up, whichever comes 
first. DMC was categorized in chemotherapy, hospitalizations, and other outpa-
tient costs. Further analysis was conducted for chemotherapy and hospitaliza-
tions. Results: From 735 patients with CLL identified in the database, 164 met 
eligibility criteria and were included in the analysis, representing a total of 100 
patients-years. Total DMC in this population was R$ 16,555,421 (mean cost of R$ 
165,827 per patient-year), from which R$ 9,451,124 (57%) are related to chemo-
therapy, R$ 5,341,862 (32%) to hospitalizations and R$ 1,762,434 (11%) to other 
outpatient costs. Outpatient laboratory exams accounted for only a small fraction 
(R$ 176,545, 1%) of DMC, and only one patient had a record of radiotherapy (< 1% 
of DMC). A total of 326 hospitalizations were identified in 79 (48%) patients, with 
an average cost of R$ 16,386 ± 29,185 per hospitalization. Chemotherapy drugs 
accounted for 71% of the total costs with chemotherapy, the rest divided between 
other drugs (12%), disposable devices (6%), hospital facility fees (5%) and other 
costs (6%). cOnclusiOns: Patients with CLL represent a significant economic 
burden to private payers. Chemotherapy and hospitalization costs accounts for 
almost 90% of the total costs.
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Objectives: Recently, MBC-HR+ was found to have a diverse pattern of response to 
the treatment compared to other MBC. Our aim is to determine the costs of treat-
ment associated with this disease, from the perspective of BPS. MethOds: A large 
private database of medical claims for chemotherapy (Ch) (Evidencias Database) 
was searched in order to identify MBC-HR+, that were treated in the last two years 
(2011-12). We extracted data regarding treatment received, length of the treatment 
and antropometric data for each MBC-HR+ patient. After, medical literature was 
performed for studies of MBC-HR+ treatments and the same data was extracted. 
Based on the combination of real-world (RW) and published data we constructed 
a decision tree, considering three groups of MBC-HR+, according to the sites of 
metastasis: bone exclusive (B), Visceral exclusive (V) and bone plus visceral (BV). 
For each group, we calculated the costs of the treatment plus adverse events, by a 
micro-costing approach. We simulated a cohort of 100 patients with MBC-HR+ in a 
decision tree, to obtain the costs for each group and a mean cost/ patient. Results: 
RW data showed the following distribution of patients: B 38%, V 42% BV 20%. Lengths 
of treatment (in months) were B: 25.1 to 30.5; V 16.1; BV 14 to 19.6. Most com-
monly used treatments were, B – two hormonal lines, fulvestrant and three lines of 
Ch. V – Four lines of Ch; BV- one hormonal line, fulvestrant, three lines of Ch. Most 
used Ch drugs were docetaxel, paclitaxel and gemcitabine. Mean costs/patient/
group, considering hormones, Ch, bisphosphonates, hospitalization, infusion, evalu-
ations of the disease, radiation therapy and adverse events were: B- R$ 135,744 (US$ 
67,872); V R$ 129,079 (US$64,539) and BV R$ 117,172 (US$58,568). cOnclusiOns: 
MBC-HR+ is associated to a high cost of treatment under the BPS perspective.
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Objectives: Targeted therapies shows marked clinical improvements over standard 
treatments such as interferon alfa (IFNa) in the treatment of advanced/metastatic 
renal cell carcinoma (mRCC). We report an updated cost-effectiveness analysis of 
pazopanib, sunitinib, and bevacizumab (the later associated INFa) as first line treat-
ments for mRCC under the Brazilian public health care perspective. In previous 
analysis, taxation was accounted exclusively for pazopanib’s price.[Value Health 
2012;15(4):A218] The present analysis applied ex-factory 0% tax prices, where now 
all comparisons were made under tax waiver programs. MethOds: A Markov model 
was designed to simulate mRCC progression, mortality and costs. The assessed 
time-horizon was 2 years. An indirect comparison estimated the relative efficacy 
and safety of the targeted therapies in mRCC patients. Costs and consequences of 
disease treatment were computed for each comparator. Only direct medical costs 
were considered and reported in 2013 Brazilian currency (1BRL= 0.50USD). Drug 
prices derived from official price list (i.e., CMED). Disease management costs were 
those from a public reimbursement database (i.e., SIGTAP). Costs and outcomes 
were discounted at 5% yearly. Outcomes assessed were progression-free survival 
(PFS) and quality-adjusted life years (QALYs). Stochastic simulations tested model 
robustness. Results: The indirect PFS hazard ratio (< 1 favours pazopanib [95%CI]) 
indicated that pazopanib is not statistically different from sunitinib (0.93 [0.56, 
1.56]) or bevacizumab+IFNa (0.79 [0.48, 1.32]). A recent head-to-head clinical study 
(COMPARZ) of pazopanib versus sunitinib confirmed indirect results. Estimated 
costs and QALYs were BRL 93,389.88 and 0.90 for pazopanib, BRL 124,923.36 and 
0.93 for sunitinib, and BRL 185,942.43 and 0.88 for bevacizumab+INFa. Propabilistic 
analysis showed favourable economic results to pazopanib in > 90% of simula-
tions when compared to sunitinib. Bevacizumab+INFa was dominated in all sce-
narios. cOnclusiOns: Pazopanib reported significantly lower costs and similar 
benefits against studied comparators as first line treatment of patients diagnosed 
with mRCC under the Brazilian public health care perspective.
